Characterizing the Influence of Preload Dosing on Percent Signal Recovery (PSR) and Cerebral Blood Volume (CBV) Measurements in a Patient Population with High-Grade Glioma Using Dynamic Susceptibility Contrast MRI
With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved for accurate relative cerebral blood volume (rCBV) measurements. Leakage effects can be dimished by administration of a preload dose before im...
Saved in:
Published in | Tomography (Ann Arbor) Vol. 3; no. 2; pp. 89 - 95 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Grapho Publications, LLC
01.06.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved for accurate relative cerebral blood volume (rCBV) measurements. Leakage effects can be dimished by administration of a preload dose before imaging and/or specific postprocessing steps. This study compares the consistency of both PSR and rCBV measurements as a function of varying preload doses in a retrospective analysis of 14 subjects with high-grade gliomas. The scans consisted of 6 DSC-MRI scans during 6 sequential bolus injections (0.05 mmol/kg). Mean PSR was calculated for tumor and normal-appearing white matter regions of interest. DSC-MRI data were corrected for leakage effects before computing mean tumor rCBV. Statistical differences were seen across varying preloads for tumor PSR (P value = 4.57E-24). Tumor rCBV values did not exhibit statistically significant differences across preloads (P value = .14) and were found to be highly consistent for clinically relevant preloads (intraclass correlation coefficient = 0.93). For a 0.05 mmol/kg injection bolus and pulse sequence parameters used, the highest PSR contrast between normal-appearing white matter and tumor occurs when no preload is used. This suggests that studies using PSR as a biomarker should acquire DSC-MRI data without preload. The finding that leakage-corrected rCBV values do not depend on the presence or dose of preload contradicts that of previous studies with dissimilar acquisition protocols. This further confirms the sensitivity of rCBV to preload dosing schemes and pulse sequence parameters and highlights the importance of standardization efforts for achieving multisite rCBV consistency. |
---|---|
AbstractList | With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved for accurate relative cerebral blood volume (rCBV) measurements. Leakage effects can be dimished by administration of a preload dose before imaging and/or specific postprocessing steps. This study compares the consistency of both PSR and rCBV measurements as a function of varying preload doses in a retrospective analysis of 14 subjects with high-grade gliomas. The scans consisted of 6 DSC-MRI scans during 6 sequential bolus injections (0.05 mmol/kg). Mean PSR was calculated for tumor and normal-appearing white matter regions of interest. DSC-MRI data were corrected for leakage effects before computing mean tumor rCBV. Statistical differences were seen across varying preloads for tumor PSR (P value = 4.57E-24). Tumor rCBV values did not exhibit statistically significant differences across preloads (P value = .14) and were found to be highly consistent for clinically relevant preloads (intraclass correlation coefficient = 0.93). For a 0.05 mmol/kg injection bolus and pulse sequence parameters used, the highest PSR contrast between normal-appearing white matter and tumor occurs when no preload is used. This suggests that studies using PSR as a biomarker should acquire DSC-MRI data without preload. The finding that leakage-corrected rCBV values do not depend on the presence or dose of preload contradicts that of previous studies with dissimilar acquisition protocols. This further confirms the sensitivity of rCBV to preload dosing schemes and pulse sequence parameters and highlights the importance of standardization efforts for achieving multisite rCBV consistency.With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved for accurate relative cerebral blood volume (rCBV) measurements. Leakage effects can be dimished by administration of a preload dose before imaging and/or specific postprocessing steps. This study compares the consistency of both PSR and rCBV measurements as a function of varying preload doses in a retrospective analysis of 14 subjects with high-grade gliomas. The scans consisted of 6 DSC-MRI scans during 6 sequential bolus injections (0.05 mmol/kg). Mean PSR was calculated for tumor and normal-appearing white matter regions of interest. DSC-MRI data were corrected for leakage effects before computing mean tumor rCBV. Statistical differences were seen across varying preloads for tumor PSR (P value = 4.57E-24). Tumor rCBV values did not exhibit statistically significant differences across preloads (P value = .14) and were found to be highly consistent for clinically relevant preloads (intraclass correlation coefficient = 0.93). For a 0.05 mmol/kg injection bolus and pulse sequence parameters used, the highest PSR contrast between normal-appearing white matter and tumor occurs when no preload is used. This suggests that studies using PSR as a biomarker should acquire DSC-MRI data without preload. The finding that leakage-corrected rCBV values do not depend on the presence or dose of preload contradicts that of previous studies with dissimilar acquisition protocols. This further confirms the sensitivity of rCBV to preload dosing schemes and pulse sequence parameters and highlights the importance of standardization efforts for achieving multisite rCBV consistency. With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved for accurate relative cerebral blood volume (rCBV) measurements. Leakage effects can be dimished by administration of a preload dose before imaging and/or specific postprocessing steps. This study compares the consistency of both PSR and rCBV measurements as a function of varying preload doses in a retrospective analysis of 14 subjects with high-grade gliomas. The scans consisted of 6 DSC-MRI scans during 6 sequential bolus injections (0.05 mmol/kg). Mean PSR was calculated for tumor and normal-appearing white matter regions of interest. DSC-MRI data were corrected for leakage effects before computing mean tumor rCBV. Statistical differences were seen across varying preloads for tumor PSR (P value = 4.57E-24). Tumor rCBV values did not exhibit statistically significant differences across preloads (P value = .14) and were found to be highly consistent for clinically relevant preloads (intraclass correlation coefficient = 0.93). For a 0.05 mmol/kg injection bolus and pulse sequence parameters used, the highest PSR contrast between normal-appearing white matter and tumor occurs when no preload is used. This suggests that studies using PSR as a biomarker should acquire DSC-MRI data without preload. The finding that leakage-corrected rCBV values do not depend on the presence or dose of preload contradicts that of previous studies with dissimilar acquisition protocols. This further confirms the sensitivity of rCBV to preload dosing schemes and pulse sequence parameters and highlights the importance of standardization efforts for achieving multisite rCBV consistency. With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved for accurate relative cerebral blood volume (rCBV) measurements. Leakage effects can be dimished by administration of a preload dose before imaging and/or specific postprocessing steps. This study compares the consistency of both PSR and rCBV measurements as a function of varying preload doses in a retrospective analysis of 14 subjects with high-grade gliomas. The scans consisted of 6 DSC-MRI scans during 6 sequential bolus injections (0.05 mmol/kg). Mean PSR was calculated for tumor and normal-appearing white matter regions of interest. DSC-MRI data were corrected for leakage effects before computing mean tumor rCBV. Statistical differences were seen across varying preloads for tumor PSR ( P value = 4.57E-24). Tumor rCBV values did not exhibit statistically significant differences across preloads ( P value = .14) and were found to be highly consistent for clinically relevant preloads (intraclass correlation coefficient = 0.93). For a 0.05 mmol/kg injection bolus and pulse sequence parameters used, the highest PSR contrast between normal-appearing white matter and tumor occurs when no preload is used. This suggests that studies using PSR as a biomarker should acquire DSC-MRI data without preload. The finding that leakage-corrected rCBV values do not depend on the presence or dose of preload contradicts that of previous studies with dissimilar acquisition protocols. This further confirms the sensitivity of rCBV to preload dosing schemes and pulse sequence parameters and highlights the importance of standardization efforts for achieving multisite rCBV consistency. With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved for accurate relative cerebral blood volume (rCBV) measurements. Leakage effects can be dimished by administration of a preload dose before imaging and/or specific postprocessing steps. This study compares the consistency of both PSR and rCBV measurements as a function of varying preload doses in a retrospective analysis of 14 subjects with high-grade gliomas. The scans consisted of 6 DSC-MRI scans during 6 sequential bolus injections (0.05 mmol/kg). Mean PSR was calculated for tumor and normal-appearing white matter regions of interest. DSC-MRI data were corrected for leakage effects before computing mean tumor rCBV. Statistical differences were seen across varying preloads for tumor PSR ( value = 4.57E-24). Tumor rCBV values did not exhibit statistically significant differences across preloads ( value = .14) and were found to be highly consistent for clinically relevant preloads (intraclass correlation coefficient = 0.93). For a 0.05 mmol/kg injection bolus and pulse sequence parameters used, the highest PSR contrast between normal-appearing white matter and tumor occurs when no preload is used. This suggests that studies using PSR as a biomarker should acquire DSC-MRI data without preload. The finding that leakage-corrected rCBV values do not depend on the presence or dose of preload contradicts that of previous studies with dissimilar acquisition protocols. This further confirms the sensitivity of rCBV to preload dosing schemes and pulse sequence parameters and highlights the importance of standardization efforts for achieving multisite rCBV consistency. |
Author | Baxter, Leslie C. Bell, Laura C. Quarles, C. Chad McGee, Samuel C. Hu, Leland S. Stokes, Ashley M. |
Author_xml | – sequence: 1 givenname: Laura C. surname: Bell fullname: Bell, Laura C. – sequence: 2 givenname: Leland S. surname: Hu fullname: Hu, Leland S. – sequence: 3 givenname: Ashley M. surname: Stokes fullname: Stokes, Ashley M. – sequence: 4 givenname: Samuel C. surname: McGee fullname: McGee, Samuel C. – sequence: 5 givenname: Leslie C. surname: Baxter fullname: Baxter, Leslie C. – sequence: 6 givenname: C. Chad surname: Quarles fullname: Quarles, C. Chad |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28825039$$D View this record in MEDLINE/PubMed |
BookMark | eNp1UsFuEzEQXaEiWko_gAuaY3pI8K6z2fUFiW4hjdSKKKEVN8vrnU0cee1ge4vCf_I_OGmLChKWJY80b96bGb_XyZGxBpPkbUpGaUlL-n4zCrYbZSQtRiSe8YvkJKMFG6aUfTt6Fh8nZ95vIiIjWbzFq-Q4K8ssJ5SdJL-qtXBCBnTqpzIrCGuEmWl1j0Yi2BbmDrUVDVxav89bA3N0Ek2ApVoZoWGB0t6j28FgvlycgzANVOiwdjF3oa1t4M7qvkMYVBd353CDwvcOu8jgQRkQMBdB7fnmdtvrGEeJHyqs4Uqt1sOpEw3CVCvbCbg9tHC5M6JTEpa9l7gNqlZahR1U1gQnfICbxexN8rIV2uPZ43ua3H7-9LW6Gl5_mc6qj9dDSRkLwwyLXJRYEkLHbZHJ8SQlNc1zksqWTrCciIbSbMIIpqLM66Kts5qlgrW1pASZpKfJhwfebV932OzXEsfmW6c64XbcCsX_zhi15it7z_M8L0jOIsHgkcDZ7z36wDsVp9JaGLS95ymjhNF8QvIIffdc64_I019GQPEAkM5677DlUoXDPqO00jwl_GAcvuHROHxvHH4wTqxM_6l8Iv9_zW9iacqB |
CitedBy_id | crossref_primary_10_1007_s11060_019_03244_6 crossref_primary_10_1016_j_xcrm_2024_101464 crossref_primary_10_3389_fradi_2022_809373 crossref_primary_10_1007_s00234_020_02522_9 crossref_primary_10_1016_j_neurad_2018_04_006 crossref_primary_10_1038_s41467_023_41559_1 crossref_primary_10_1002_jmri_26837 crossref_primary_10_1016_j_artmed_2023_102607 crossref_primary_10_1016_j_neuroimage_2018_04_069 crossref_primary_10_1111_jon_13183 crossref_primary_10_1007_s00330_023_09917_1 crossref_primary_10_1177_0271678X211039597 crossref_primary_10_1007_s00330_023_09729_3 crossref_primary_10_3174_ajnr_A8099 |
ContentType | Journal Article |
Copyright | 2017 The Authors. Published by Grapho Publications, LLC 2017 Grapho Publications, LLC |
Copyright_xml | – notice: 2017 The Authors. Published by Grapho Publications, LLC 2017 Grapho Publications, LLC |
DBID | AAYXX CITATION NPM 7X8 5PM |
DOI | 10.18383/j.tom.2017.00004 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2379-139X |
EndPage | 95 |
ExternalDocumentID | PMC5557059 28825039 10_18383_j_tom_2017_00004 |
Genre | Journal Article |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01 CA158079 |
GroupedDBID | 53G AAYXX AFZYC ALMA_UNASSIGNED_HOLDINGS CITATION GROUPED_DOAJ HYE MODMG M~E OK1 PGMZT RPM EMOBN IAO IGS ITC NPM 7X8 5PM |
ID | FETCH-LOGICAL-c399t-2e75a8e80034f72c4610b35501cf36e86ad332690e1a85b7fb2b91a9fbc30e9c3 |
ISSN | 2379-139X 2379-1381 |
IngestDate | Thu Aug 21 18:32:31 EDT 2025 Fri Jul 11 12:40:43 EDT 2025 Thu Jan 02 23:12:10 EST 2025 Thu Apr 24 23:01:41 EDT 2025 Tue Jul 01 01:51:00 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | percent signal recovery DSC-MRI preload doses relative cerebral blood volume |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c399t-2e75a8e80034f72c4610b35501cf36e86ad332690e1a85b7fb2b91a9fbc30e9c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://dx.doi.org/10.18383/j.tom.2017.00004 |
PMID | 28825039 |
PQID | 1930935605 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5557059 proquest_miscellaneous_1930935605 pubmed_primary_28825039 crossref_citationtrail_10_18383_j_tom_2017_00004 crossref_primary_10_18383_j_tom_2017_00004 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-06-01 2017-Jun 20170601 |
PublicationDateYYYYMMDD | 2017-06-01 |
PublicationDate_xml | – month: 06 year: 2017 text: 2017-06-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Ann Abor, Michigan |
PublicationTitle | Tomography (Ann Arbor) |
PublicationTitleAlternate | Tomography |
PublicationYear | 2017 |
Publisher | Grapho Publications, LLC |
Publisher_xml | – name: Grapho Publications, LLC |
References | 15597757 - J Neurosurg. 2004 Dec;101(6):970-6 27505026 - Br J Radiol. 2016 Oct;89(1066):20160476 18780827 - Radiology. 2008 Nov;249(2):601-13 19585599 - Magn Reson Med. 2009 Sep;62(3):672-81 26362714 - Magn Reson Med. 2016 Aug;76(2):613-25 16421765 - Acta Neurochir (Wien). 2006 Mar;148(3):277-85; discussion 285 21505483 - J Cereb Blood Flow Metab. 2011 Oct;31(10 ):2041-53 19059349 - Neuroimage. 2009 Mar;45(1 Suppl):S173-86 23413249 - AJNR Am J Neuroradiol. 2013 Jul;34(7):1364-9 19749223 - AJNR Am J Neuroradiol. 2010 Jan;31(1):40-8 15502131 - AJNR Am J Neuroradiol. 2004 Oct;25(9):1524-32 28034995 - AJNR Am J Neuroradiol. 2017 Mar;38(3):478-484 26971534 - J Magn Reson Imaging. 2016 Nov;44(5):1229-1237 16611779 - AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67 19789240 - Radiology. 2009 Nov;253(2):486-96 17659630 - Magn Reson Med. 2007 Jul;58(1):70-81 25227668 - Magn Reson Med. 2015 Sep;74(3):772-84 18372467 - Radiology. 2008 Apr;247(1):170-8 25907520 - AJNR Am J Neuroradiol. 2015 Jun;36(6):E41-51 19056837 - AJNR Am J Neuroradiol. 2009 Mar;30(3):552-8 25436828 - Am J Clin Oncol. 2017 Jun;40(3):228-234 26294301 - J Nucl Med. 2015 Oct;56(10 ):1554-61 22322605 - AJNR Am J Neuroradiol. 2012 Jun;33(6):1081-7 22281731 - J Magn Reson Imaging. 2012 Jun;35(6):1472-7 |
References_xml | – reference: 19056837 - AJNR Am J Neuroradiol. 2009 Mar;30(3):552-8 – reference: 16611779 - AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67 – reference: 25227668 - Magn Reson Med. 2015 Sep;74(3):772-84 – reference: 26362714 - Magn Reson Med. 2016 Aug;76(2):613-25 – reference: 19059349 - Neuroimage. 2009 Mar;45(1 Suppl):S173-86 – reference: 17659630 - Magn Reson Med. 2007 Jul;58(1):70-81 – reference: 21505483 - J Cereb Blood Flow Metab. 2011 Oct;31(10 ):2041-53 – reference: 23413249 - AJNR Am J Neuroradiol. 2013 Jul;34(7):1364-9 – reference: 28034995 - AJNR Am J Neuroradiol. 2017 Mar;38(3):478-484 – reference: 22281731 - J Magn Reson Imaging. 2012 Jun;35(6):1472-7 – reference: 18780827 - Radiology. 2008 Nov;249(2):601-13 – reference: 19585599 - Magn Reson Med. 2009 Sep;62(3):672-81 – reference: 15597757 - J Neurosurg. 2004 Dec;101(6):970-6 – reference: 26971534 - J Magn Reson Imaging. 2016 Nov;44(5):1229-1237 – reference: 25436828 - Am J Clin Oncol. 2017 Jun;40(3):228-234 – reference: 16421765 - Acta Neurochir (Wien). 2006 Mar;148(3):277-85; discussion 285 – reference: 15502131 - AJNR Am J Neuroradiol. 2004 Oct;25(9):1524-32 – reference: 22322605 - AJNR Am J Neuroradiol. 2012 Jun;33(6):1081-7 – reference: 25907520 - AJNR Am J Neuroradiol. 2015 Jun;36(6):E41-51 – reference: 26294301 - J Nucl Med. 2015 Oct;56(10 ):1554-61 – reference: 18372467 - Radiology. 2008 Apr;247(1):170-8 – reference: 27505026 - Br J Radiol. 2016 Oct;89(1066):20160476 – reference: 19789240 - Radiology. 2009 Nov;253(2):486-96 – reference: 19749223 - AJNR Am J Neuroradiol. 2010 Jan;31(1):40-8 |
SSID | ssj0002022027 |
Score | 2.0996468 |
Snippet | With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 89 |
Title | Characterizing the Influence of Preload Dosing on Percent Signal Recovery (PSR) and Cerebral Blood Volume (CBV) Measurements in a Patient Population with High-Grade Glioma Using Dynamic Susceptibility Contrast MRI |
URI | https://www.ncbi.nlm.nih.gov/pubmed/28825039 https://www.proquest.com/docview/1930935605 https://pubmed.ncbi.nlm.nih.gov/PMC5557059 |
Volume | 3 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2FIiFeEHfCTYPEQ4tlsNd2HD-m4dIiFUVNW_Ut2rU3JJDYVeI80P_kD_gQZnbXjpMCAl6iyN5sLM3x7Mzs2TOMvZQUdMSZ52ZSxm4os8BNeCdAg_hc8mwsQqlZvp86B6fhx_PovNX60WAtrUr5Or385bmS_7EqXkO70inZf7BsPSlewO9oX_xEC-PnX9m4X6stX1anng6rpiOa3LZQs0JkGCXrigAaekA8lrx0htPPuZbVT4nCqXf8B8NjKhFQIb2vFrSfPHP2idbunGkPpvd7989ozNG6sKjptIKU_ulgpTOo-4GhvyknmkbifliIjHgd02IuHMNRePstF8TKH66WmlejKbrknajWvCydo-PDZth8UsyttDY9RS_Pnd5CUqGhLmNU54zonLdYl34PVvqimmmGal1OKouvxj32lhPyis2Db7ZzgJiv1MxOZKsifrxmbxnnyYM4IX1Fv-npgwagecNrmyZGVxaTLmbvejUpC9Is8I3YZdgci3i4mGt0cUxVIs8IM20peFe3rrHrHJMZ3kj8v-itYE4VKN0F0T603X6nB3iz_fckX20n3IylriRI2zzfRuB0cpvdshkP9Ax877CWyu-yG0eW03GPfd9EMSCKoUYxFGOwKAaDYihysCgGg2KoUAy7iOE9QFNDhWDQCAaDYNhF_O5BE70wzUGARS-s0QuEXlijFwx6QaMXLHphE71QoRcQvffZ6ft3J_0D1zYbcVOM0UuXqzgSXdUlwaZxzFPqQyAxGPf8dBx0VLcjsgBTncRTvuhGMh5LLhNfJGOZBp5K0uAB28mLXD1igMukijiVfyQPkzBMaKGLUpnJSEjJVZt5ldlGqVXip4YwsxFl5GR0TMnR6CMy-kgbvc1e1T-5MDI0fxr8osLCCBcL2gEUuSpWyxFma0R86HhRmz002Kinq0DVZvEGauoBJES_eSefTrQgfUQ6flHy-LdzPmE31y_pU7ZTLlbqGQbzpXyu34WfR_D1Vw |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterizing+the+Influence+of+Preload+Dosing+on+Percent+Signal+Recovery+%28PSR%29+and+Cerebral+Blood+Volume+%28CBV%29+Measurements+in+a+Patient+Population+With+High-Grade+Glioma+Using+Dynamic+Susceptibility+Contrast+MRI&rft.jtitle=Tomography+%28Ann+Arbor%29&rft.au=Bell%2C+Laura+C&rft.au=Hu%2C+Leland+S&rft.au=Stokes%2C+Ashley+M&rft.au=McGee%2C+Samuel+C&rft.date=2017-06-01&rft.issn=2379-1381&rft.volume=3&rft.issue=2&rft.spage=89&rft_id=info:doi/10.18383%2Fj.tom.2017.00004&rft_id=info%3Apmid%2F28825039&rft.externalDocID=28825039 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2379-139X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2379-139X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2379-139X&client=summon |